114 results about "Renal filtrate" patented technology

The invention relates to a weight loss intervention method and device for chronic renal failure and obesity patients based on an individualized prescription. The method comprises the following steps: constructing a multi-modal dynamic time sequence feature vector of a patient; identifying and quantifying potential causal effects of different weight loss intervention measures on physiological outcomes of renal functions, electrolyte balance, anemia states, bone mineral metabolism and weight indexes of the CKD patient according to a dual robust estimator; dynamically constructing a weight loss intervention measure causal model according to the potential causal effect of the physiological outcome of each patient and the physiological and pathological background; and inputting the multi-modal dynamic time sequence feature vector of the patient into a weight loss intervention measure causal model, and generating a daily diet scheme, an exercise scheme and corresponding high-confidence risk early warning and causal explanation of the patient. The method overcomes the limitation that the traditional method only pays attention to correlation and cannot clearly determine the intervention effect, ensures that the causal atlas and the intervention scheme are optimized according to the real-time change state of the patient, and realizes a real dynamic prescription.

The invention provides a traditional Chinese medicine composition for treating chronic kidney diseases and a preparation method and application thereof, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 16 to 24 parts of astragalus membranaceus, 24 to 36 parts of poria cocos, 24 to 36 parts of motherwort herb, 16 to 24 parts of herba pyrolae, 24 to 36 parts of hairyvein agrimony, 24 to 36 parts of herba ardisiae japonicae, 16 to 24 parts of dianthus superbus, 16 to 24 parts of cluster mallow fruit and 6.4 to 9.6 parts of tetrapanax papyriferus. The invention further provides a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition disclosed by the invention can safely and effectively improve the renal function of patients suffering from chronic kidney diseases such as qi deficiency, blood stasis and damp turbidity accumulation, relieve clinical symptoms and delay disease progression, and a traditional Chinese medicine scheme with an exact curative effect is provided for clinically treating the diseases.

Apparatus, systems, and methods for achieving thermally-induced renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a treatment device comprising an elongated shaft. The elongated shaft is sized and configured to deliver a thermal element to a renal artery via an intravascular path. Thermally-induced renal neuromodulation may be achieved via direct and / or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers.

This utility model relates to the field of urine collection bag technology and discloses a urine collection bag for bladder irrigation in urological patients. It includes a lifting arm and a urine collection bag. A hook is fixedly connected to the middle of the upper surface of the lifting arm, and a warning light is installed in the middle of one side of the lifting arm. A power supply is installed inside the lifting arm. Slides are formed on both sides of the lifting arm. A conductive block is fixedly connected to one side of the bottom wall of the slide, and a spring is fixedly connected to the other side of the bottom wall of the slide. An inlet pipe is fixedly connected to one side of the upper surface of the urine collection bag, and a drain pipe is fixedly connected to the middle of the lower surface of the urine collection bag. This urine collection bag for bladder irrigation, through the design of an observation window and built-in scale lines, reduces the interference of bag deformation and light refraction on readings. Nursing staff can intuitively and accurately read the volume of irrigation waste fluid, ensuring accurate recording of intake and output balance, and providing reliable data support for assessing the patient's bladder irrigation effect, bleeding, and renal function recovery.

The invention relates to the field of biological medicines, and discloses an application of an anti-thymocyte immune globulin preparation in liver transplantation immune induction, which comprises a use method and a dosage of anti-thymocyte immune globulin as an immune inducer in a liver transplantation recipient. Clinical cases prove that liver transplantation recipients use the anti-thymocyte immune globulin as immunosuppressive induction, so that the liver function and lymphocyte level can be quickly recovered to normal ranges, no obvious influence is caused on renal function, the occurrence rate of acute rejection reaction is reduced, the cytomegalovirus infection rate is not increased, and the anti-thymocyte immune globulin can be applied to liver transplantation recipients. Clinical application of the anti-thymocyte immune globulin in immune induction treatment of liver transplantation recipients is expanded, and the anti-thymocyte immune globulin has a great application prospect.

Provided is a renal function maintenance and protection agent comprising as an active ingredient of a triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA), which can be used as a pharmaceutical or food composition.A triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA) is used as an active ingredient for renal function maintenance and protection agents.

Provided herein are methods of improving kidney function in a subject in need thereof.

Verdazil derivative compounds and compositions thereof, useful as contrast agents for biomedical imaging, are provided. The compounds and compositions of this disclosure can be used, for example, for quantitative and / or qualitative assessment of glomerular filtration rate (GFR) in subjects, providing a reliable and rapid assessment of renal function.

The invention relates to the technical field of biomedicine, in particular to a preparation method of sequential targeting mesoporous manganese oxide nano-enzyme and application of the sequential targeting mesoporous manganese oxide nano-enzyme in treatment of ischemia reperfusion induced acute kidney injury. Adding a potassium permanganate solution into the silicon dioxide nanoparticle dispersion liquid under ultrasonic waves, and carrying out alkali etching to obtain mesoporous manganese oxide nanoparticles (HMN); and after surface amination modification, connecting with a mixed PEG spacer layer, and reacting with thiolated SS31 and azidoacyl hyaluronic acid to obtain the nano-enzyme. The preparation can effectively penetrate through a damaged glomerulus filtration barrier and is passively enriched in a damaged kidney, damaged renal tubular epithelial cells over-express CD44 receptor mediated hyaluronic acid modified nano-particle endocytosis is enhanced, SS31 modified nano-particles achieve lysosome escape mitochondrial targeting in cells, the level of active oxygen in mitochondria can be reduced, and the activity of the mitochondria can be improved. The mitochondrial function is recovered, the renal function and tissue pathological injury are improved, and accurate anti-oxidation treatment on the acute kidney injury is realized.

According to the RNA binding protein HuR inhibitor and the anti-fibrosis application thereof, the compound provided by the invention has obvious inhibitory activity on HuR protein, has a good anti-renal fibrosis effect, can obviously reduce protein and mRNA expression levels of fibronectin (FN1) and alpha-smooth muscle actin (alpha-SMA), can improve renal function impairment, and can be used for preparing the anti-fibrosis medicine for treating renal fibrosis. The levels of blood urea nitrogen (BUN) and creatinine (Cr) which are commonly used for evaluating the renal function are reduced, and the compound can be used for preparing the medicine for treating the chronic kidney disease.

The invention discloses a traditional Chinese medicine composition for treating hyperuricemia and application thereof, and belongs to the technical field of traditional Chinese medicines. The preparation method of the traditional Chinese medicine composition comprises the following steps: mixing ganoderma lucidum spore powder and idesia polycarpa fruit powder according to a mass part ratio of (10-90): (90-10), extracting by using a supercritical CO2 fluid extraction technology to obtain an extract phase, then carrying out decompression analysis to precipitate an extract, and drying to obtain traditional Chinese medicine composition powder. The invention provides the traditional Chinese medicine composition compounded by the ganoderma lucidum spore oil and the idesia oil, and cell experiments and animal experiments prove that the traditional Chinese medicine composition can remarkably inhibit uric acid synthesis and reabsorption, so that the level of serum uric acid is reduced, renal function impairment caused by hyperuricemia is improved, and the curative effect is improved. The compound can be used as a functional raw material for preparing a product for treating hyperuricemia or improving kidney injury caused by hyperuricemia; the raw materials are easy to obtain, the cost is low, the safety is high, and good development and application values are achieved.

A system and method for diagnosing a patient's renal function, the method comprising delivering a first tracer agent, transmucosally applying a first excitation light to the first tracer agent at the first monitoring site, transmucosally receiving a first fluorescent light emitted from the first tracer agent at the first monitoring site, transforming the received first fluorescent light to produce a first fluorescence signal, processing the first fluorescence signal to determine a first decay rate, and processing the first decay rate of the first fluorescent light to determine a glomerular filtration rate of the patient.

The disclosure provides means, methods, and compositions of preventing, reducing, and treating kidney failure through the administration of fibroblasts, modified fibroblasts, and / or products derived from fibroblasts. The disclosure may also concern administration of fibroblasts prior to, concurrent with, or subsequent to administration of a nephrotoxic agent results in production of renal function. In some embodiments, fibroblasts are enhanced for augmentation of nephron-regenerative properties through culture under means including hypoxia, histone deacetylase inhibitor treatment, oxytocin, and / or DNA methyltransferase inhibitors.

The invention belongs to the field of biological medicines, and particularly discloses application of extracellular vesicles EVs carrying CD35 functional molecules in preparation of medicines for treating sepsis-related multi-organ injury, preferably, the EVs are derived from human podocytes or other cells or tool cells capable of naturally or engineered expressing CD35, and the EVs are administrated through caudal vein injection and can be used for preparing medicines for treating sepsis-related multi-organ injury. Normal saline is taken as a carrier, and the dosage of 1 * 10 < 10 > EVs each time is once every 12 hours and twice continuously. It is proved for the first time that EVs carries CD35 to inhibit circulation mononuclear cell complement activation (the EVs are combined with C3b to block downstream complement cascade reaction), migration of mononuclear cells to the kidney, the heart, the liver and the lung is reduced, and therefore multi-organ inflammation damage and cell apoptosis are relieved. In a cecum ligation perforation (CLP) sepsis model, it is proved that the medicine significantly improves the survival rate of mice, improves renal functions (reduces creatinine / urea nitrogen) and kidney pathological tissue damage, and meanwhile relieves pathological damage of multiple organs of the heart, the liver and the lung. The invention provides a new treatment strategy and drug candidate for sepsis-related multi-organ dysfunction.

This invention belongs to the field of traditional Chinese medicine treatment of acute kidney injury, and provides a traditional Chinese medicine composition for treating sepsis-related acute kidney injury and its preparation method. It is prepared by mixing honeysuckle, forsythia, roasted peach kernel, raw rhubarb, raw astragalus, wine-processed angelica, cinnamon twig, mirabilite, and raw licorice in a certain proportion. It detoxifies and removes blood stasis, invigorates qi and unblocks the meridians. It is used for persistent high fever and difficulty in urination and defecation caused by internal accumulation of toxic heat and blood stasis. Symptoms include oliguria or dribbling, red tongue, and rapid pulse; it is also used for sepsis patients with the above symptoms. Treatment with the detoxifying and blood-stasis-removing granules improved survival rate, effectively restored some renal function, reduced renal tubular damage, and decreased TNF-α and IL-1β expression. Immunohistochemical and Western blot results were consistent. The detoxifying and blood-stasis-removing granules can alleviate sepsis-induced acute kidney injury.

This invention provides a traditional Chinese medicine composition for treating renal edema, pyelonephritis with ascites, and nephritis. It consists of over 20 herbs including Atractylodes lancea, Areca catechu, Saposhnikovia divaricata, and Alisma plantago-aquatica (specific formulation details can be found in the original text). It can be prepared as pills, granules, or decoctions for oral administration. Core efficacy: 1. Promotes diuresis and reduces swelling, eliminating renal ascites; 2. Clears heat and detoxifies, anti-inflammatory and antibacterial (synergistic effect on fungal infections and cervical erosion); 3. Regulates renal function and improves abnormal uric acid metabolism. Treatment plan: Mild cases: Use five basic formulas (①-⑤) composed of Codonopsis pilosula, Poria cocos, etc., taken three times daily; Severe cases: Use a potent diuretic formula containing Akebia trifoliata and Euphorbia pekinensis (one spoonful of pills twice daily); Treatment course is approximately one month, with a follow-up examination after three months. Advantages: Cure rate reaches 90%, low recurrence rate – pure traditional Chinese medicine preparation, no significant toxic side effects; also treats complications (fungal infection, cervical lesions). This treatment plan has been clinically verified through three generations and has significant efficacy in treating renal edema, ascites, and nephritis.

The present invention consists of a digital, always-online computer system designed to optimize perioperative safety through the automated integration of clinical and laboratory parameters. Unlike conventional medical calculators, this system implements a reactive logic engine that simultaneously calculates glomerular filtration rate (CKD-EPI 2021) and scores multiple risk scales (Goldman, LEE, ASA, CHA2DS2-VASc, HAS-BLED) without duplicate data entry. The system includes a drug reconciliation algorithm that cross-references the bleeding risk of the surgical procedure with the patient's renal function, generating accurate recommendations for discontinuing or continuing high-risk medications (anticoagulants, antiplatelet agents, SGLT2 inhibitors) based on current clinical evidence.

The invention belongs to the technical field of medicines, and particularly relates to application of a small molecule regulator to improvement of AKI treatment by promoting EPC cell differentiation. In order to develop a new AKI treatment scheme, the research finds that the Orticumab can promote EPC cell differentiation (not only can enhance cell viability and up-regulate an anti-inflammatory factor IL-10, but also can down-regulate proinflammatory factors TNF-alpha, IL-1beta and IL-6), so that kidney tissue damage after mouse renal ischemia reperfusion is effectively relieved, renal function deterioration is relieved, and inflammatory response is inhibited. The application shows that the Orticumab can improve the renal ischemia reperfusion injury by promoting the differentiation of EPC cells so as to play a role in protecting the renal I / R injury, and the discovery provides a new therapeutic scheme for improving AKI.

Methods of treating type 1 diabetes, improving cardiovascular health, delaying renal function decline, reducing the risk of cardiovascular death and reducing the risk of heart failure hospitalization, while minimizing adverse events such as diabetic ketoacidosis and severe hypoglycemia, using sodium-glucose cotransporter 2 (SGLT2) inhibitors are disclosed. In a preferred method, the SGLT2 inhibitor is sofogliflozin. Also disclosed are prescriptions for developing sofogliflozin and methods of administering sofogliflozin.

The invention relates to the technical field of biological medicine, and particularly discloses a platelet membrane-coated mitochondrial compound and a preparation method and application thereof, and the platelet membrane-coated mitochondrial compound comprises mitochondria extracted from mammalian tissues and a platelet membrane coating the outer layer of the mitochondria. According to the present invention, the high kidney injury targeting enrichment rate is achieved through the PMITO compound constructed by coating the mitochondria with the platelet membrane, the healthy mitochondria is accurately delivered to the focus, and the energy crisis and the cell apoptosis are directly reversed; meanwhile, the biomimetic membrane structure can actively adsorb key inflammatory factors such as TNF-alpha and IL-1beta to synergistically realize dual mechanisms of energy repair and inflammation regulation, so that renal function indexes are remarkably improved in an animal model, and tissue pathological damage is relieved; finally, a new strategy for treating the renal ischemia-reperfusion injury, which is high in targeting property, clear in curative effect and good in biological safety, is formed.

This invention belongs to the field of biomedical technology, specifically disclosing the use of neuron-derived neurotrophic factors in the preparation of drugs for the prevention and treatment of kidney stones. Using a glyoxylate-induced mouse model of kidney calcium deposition, this invention demonstrates that neuron-derived neurotrophic factors can significantly reduce kidney calcium deposition, alleviate renal tubular structural damage, and improve renal function indicators. This achieves comprehensive intervention in the entire process of kidney stone disease, from crystal formation to tissue damage to functional abnormalities, exhibiting superior technical effects compared to single stone-dissolving or stone-expelling strategies, and possesses significant application value and clinical translational potential.

The invention relates to the technical field of biological medicine, in particular to application of zinc-ginsenoside coordination nano-enzyme in treatment of diabetic nephropathy. The Zn (at) Gs-Re nano-enzyme provided by the invention not only enhances the stability and biological activity of ginsenoside Re, but also endows the ginsenoside Re with novel similar SOD / CAT enzyme activity, realizes multiple synergistic effects of resisting oxidation, resisting inflammation, resisting apoptosis, protecting mitochondria and improving renal functions, and shows remarkable superiority in the aspect of treating diabetic nephropathy and related complications.

The invention relates to application of hispidulin or pharmaceutically acceptable salts, esters and solvates thereof in preparation of medicines for treating lupus nephritis. The invention develops a new application of the hispidulin, and proves the treatment effect of the hispidulin on lupus nephritis. Meanwhile, the invention verifies that the hispidulin can obviously improve the renal function indexes (including reducing urine protein, blood urea nitrogen and serum creatinine, increasing serum albumin and improving lipid metabolism) of lupus nephritis, can relieve renal pathological injuries (including reducing glomerular mesangial hyperplasia, basilar membrane thickening, renal tubule dilatation and interstitial inflammation infiltration), and can improve the renal function indexes of lupus nephritis. Kidney immune complex deposition can be reduced (including reduction of deposition of kidney IgG and complement C3), meanwhile, it is found for the first time that angiogenin-like protein 4 (Angptl4) is a key action target for treating lupus nephritis by means of the homospidulin, and the homospidulin plays a kidney protection role by down-regulating Angptl4 expression.

The application discloses a kidney function risk information processing method based on OCTA features and clinical data, and relates to the technical field of artificial intelligence and intelligent medical treatment. Quantitative features such as blood vessel density, perfusion area, retinal thickness and choroidal vascular volume are extracted from multi-scale fundus OCTA images of a subject, and total feature data sets are constructed in combination with clinical biochemical indexes, so as to estimate glomerular filtration rate as an outcome index for binary classification labeling. Elastic network regression is adopted to screen key modeling features, and various machine learning models such as logistic regression, random forest and gradient boosting are simultaneously trained on a training set. After 5-fold cross-validation optimization, the optimal model is selected by comprehensively considering the receiver operating characteristic curve, the calibration curve and the decision curve. A nomogram is constructed based on the optimal model, and individual early kidney function decline risk probability numerical values and auxiliary reference information of the subject are outputted for reference of clinical doctors.

The present invention provides non-human animals expressing human CFB protein or chimeric (e.g., humanized) CFB protein and methods for using the same. The present invention further provides a non-human animal genome, a humanized CFB gene, and cells, tissues, organs, or non-human animals containing the non-human animal genome and the humanized CFB gene. The non-human animals obtained in this application successfully express human CFB protein or humanized CFB protein, which can be cleaved by CFD, bind to C3b, and exert similar effects in the human body. Furthermore, the non-human animals obtained in this application have complete renal function, normal blood biochemical indicators, and, more remarkably, do not exhibit the potential diseases observed in other transgenic mice known in this art.

The invention relates to a traditional Chinese medicine composition for treating acute kidney injury and a preparation method, and belongs to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 10-30 parts of raw radix astragali; 10-15 parts of codonopsis pilosula; 10 parts of rhizoma pinellinae praeparata; 10 parts of pericarpium citri reticulatae; 15 to 30 parts of loofah sponge; 15 to 30 parts of serissa japonica; and 15-30 parts of rhizoma smilacis glabrae. The traditional Chinese medicine composition disclosed by the invention has two treatment methods of tonifying qi and relieving turbidity, realizes multiple ways, treats both symptoms and root causes, is promoted to be new, has the functions of tonifying qi and relieving turbidity, has a remarkable clinical effect on treating acute renal insufficiency, and has a very good effect in the aspects of improving renal functions and protecting kidneys.

Disclosed herein include methods and compositions for pig-to-human organ xenotransplantation using genetically modified pigs with triple-gene knockouts and human gene insertions. In some embodiments, the organ xenotransplantation is a pig-to-human kidney xenotransplantation demonstrating the restoration of renal function. Also disclosed are methods and compositions for preventing acute rejection and / or reactivation of porcine herpesvirus, which contributes to advancing xenotransplantation as a viable solution to the global organ shortage.

The invention provides a traditional Chinese medicine preparation for treating type 2 diabetic nephropathy and a preparation method and application thereof, and relates to the technical field of traditional Chinese medicine. The traditional Chinese medicine reagent is characterized by comprising the following raw materials: astragalus membranaceus, prepared rehmannia root, dogwood, salvia miltiorrhiza, safflower, poria cocos, rhizoma alismatis, prepared rhubarb, codonopsis pilosula and winged euonymus twig. The traditional Chinese medicine composition has the effects of tonifying qi, activating blood, tonifying kidney and removing turbidity through cooperation of the medicines. The whole formula focuses on the pathogenesis of deficiency stasis and turbid toxin, and the treatment effect is achieved through multiple target points and multi-layer effects. Animal experiments show that the preparation can significantly relieve glomerular mesangial matrix hyperplasia and renal interstitial fibrosis. Clinical experiments show that traditional Chinese medicine symptom scores and curative effects are reduced, blood sugar is controlled, and laboratory indexes related to renal functions are improved.

The invention provides an application of selenomethionine in preparation of a medicine for preventing and / or treating cisplatin-induced acute kidney injury. The selenomethionine can resist ferroptosis without depending on GPX4, and plays a role in kidney protection. The mechanism not only comprises providing a selenium source for GPX4 synthesis through a non-sulfur conversion way, but also has the capability of directly removing reactive oxygen species (ROS) independent of GPX4, thereby achieving the effect of dual inhibition of ferroptosis. Animal experiments prove that selenomethionine can remarkably improve the renal function of a cis-platinum induced acute kidney injury model mouse and relieve tissue injury. The invention provides a new potential treatment strategy for clinical prevention and treatment of acute kidney injury caused by cisplatin and other drugs.

Described herein are methods for treating and / or preventing a kidney disease or an associated disorder as measured by an increase in estimated glomerular filtration rate (eGFR) by administering to a subject in need thereof, a combination of a sodium-glucose transport protein 2 (SGLT2) inhibitor and a compound of Formula I or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein the variables of Formula I are as defined herein.